AACR logo

More articles from Melanoma

Midkine Promotes Immunosuppression and Reduces Immunotherapy Efficacy
Cancer Discovery Dec 2020, 10 (12) OF5; DOI: 10.1158/2159-8290.CD-RW2020-157
Low-Heterogeneity Melanomas Are More Immunogenic and Less Aggressive
Cancer Discovery Nov 2019, 9 (11) 1483; DOI: 10.1158/2159-8290.CD-RW2019-144
SMAD7 Loss Promotes Phenotype Switching–Independent Melanoma
Cancer Discovery Aug 2019, 9 (8) OF14; DOI: 10.1158/2159-8290.CD-RW2019-089
Potentially Actionable MAP3K8 Alterations Are Common in Spitzoid Melanoma
Cancer Discovery May 2019, 9 (5) 574; DOI: 10.1158/2159-8290.CD-RW2019-037
Pharmacologic Inhibition of STK19 Impairs NRAS-Driven Melanoma
Cancer Discovery Apr 2019, 9 (4) OF8; DOI: 10.1158/2159-8290.CD-RW2019-017
FAK Is a Critical Mediator of GNAQ-Driven Uveal Melanoma
Cancer Discovery Apr 2019, 9 (4) 462; DOI: 10.1158/2159-8290.CD-RW2019-024
SPRED1 Is a Tumor Suppressor in Mucosal Melanoma
Cancer Discovery Dec 2018, 8 (12) 1507; DOI: 10.1158/2159-8290.CD-RW2018-196
MITF Synchronizes UV-Protection Programs in the Skin
Cancer Discovery Dec 2018, 8 (12) 1506; DOI: 10.1158/2159-8290.CD-RW2018-194
Targeting RXR Signaling May Delay Relapse in Melanoma
Cancer Discovery Sep 2018, 8 (9) 1059; DOI: 10.1158/2159-8290.CD-RW2018-123
Melanoma Risk Variants Prevent MC1R Palmitoylation and Activation
Cancer Discovery Nov 2017, 7 (11) OF16; DOI: 10.1158/2159-8290.CD-RW2017-174

Main menu